These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 33002431)

  • 1. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
    Vale CL; Fisher D; Kneebone A; Parker C; Pearse M; Richaud P; Sargos P; Sydes MR; Brawley C; Brihoum M; Brown C; Chabaud S; Cook A; Forcat S; Fraser-Browne C; Latorzeff I; Parmar MKB; Tierney JF;
    Lancet; 2020 Oct; 396(10260):1422-1431. PubMed ID: 33002431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
    Parker CC; Clarke NW; Cook AD; Kynaston HG; Petersen PM; Catton C; Cross W; Logue J; Parulekar W; Payne H; Persad R; Pickering H; Saad F; Anderson J; Bahl A; Bottomley D; Brasso K; Chahal R; Cooke PW; Eddy B; Gibbs S; Goh C; Gujral S; Heath C; Henderson A; Jaganathan R; Jakobsen H; James ND; Kanaga Sundaram S; Lees K; Lester J; Lindberg H; Money-Kyrle J; Morris S; O'Sullivan J; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Røder MA; Sayers I; Simms M; Wilson J; Zarkar A; Parmar MKB; Sydes MR
    Lancet; 2020 Oct; 396(10260):1413-1421. PubMed ID: 33002429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
    Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
    Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
    Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
    Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).
    Parker CC; Petersen PM; Cook AD; Clarke NW; Catton C; Cross WR; Kynaston H; Parulekar WR; Persad RA; Saad F; Bower L; Durkan GC; Logue J; Maniatis C; Noor D; Payne H; Anderson J; Bahl AK; Bashir F; Bottomley DM; Brasso K; Capaldi L; Chung C; Cooke PW; Donohue JF; Eddy B; Heath CM; Henderson A; Henry A; Jaganathan R; Jakobsen H; James ND; Joseph J; Lees K; Lester J; Lindberg H; Makar A; Morris SL; Oommen N; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Ramani V; Røder A; Sayers I; Simms M; Srinivasan V; Sundaram S; Tarver KL; Tran A; Wells P; Wilson J; Zarkar AM; Parmar MKB; Sydes MR;
    Ann Oncol; 2024 Jul; 35(7):656-666. PubMed ID: 38583574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
    Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
    Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
    Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
    Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
    Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
    Parker CC; Clarke NW; Cook AD; Kynaston H; Catton CN; Cross WR; Petersen PM; Persad RA; Saad F; Bower LC; Logue J; Payne H; Forcat S; Goldstein C; Murphy C; Anderson J; Barkati M; Bottomley DM; Branagan J; Choudhury A; Chung PWM; Cogley L; Goh CL; Hoskin P; Khoo V; Malone SC; Masters L; Morris SL; Nabid A; Ong AD; Raman R; Tarver KL; Tree AC; Worlding J; Wylie JP; Zarkar AM; Parulekar WR; Parmar MKB; Sydes MR;
    Lancet; 2024 Jun; 403(10442):2405-2415. PubMed ID: 38763154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis.
    Tao R; Dai J; Bai Y; Yang J; Sun G; Zhang X; Zhao J; Zeng H; Shen P
    Radiat Oncol; 2019 Nov; 14(1):197. PubMed ID: 31706339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
    Parker CC; Kynaston H; Cook AD; Clarke NW; Catton CN; Cross WR; Petersen PM; Persad RA; Pugh CA; Saad F; Logue J; Payne H; Bower LC; Brawley C; Rauchenberger M; Barkati M; Bottomley DM; Brasso K; Chung HT; Chung PWM; Conroy R; Falconer A; Ford V; Goh CL; Heath CM; James ND; Kim-Sing C; Kodavatiganti R; Malone SC; Morris SL; Nabid A; Ong AD; Raman R; Rodda S; Wells P; Worlding J; Parulekar WR; Parmar MKB; Sydes MR;
    Lancet; 2024 Jun; 403(10442):2416-2425. PubMed ID: 38763153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.